argenx NV ADR (ARGX)vsMilestone Pharmaceuticals Inc (MIST)
ARGX
argenx NV ADR
$962.22
+1.73%
HEALTHCARE · Cap: $61.92B
MIST
Milestone Pharmaceuticals Inc
$0.79
-7.78%
HEALTHCARE · Cap: $110.70M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 226766% more annual revenue ($5.32B vs $2.34M). ARGX leads profitability with a 32.3% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
MIST
Avoid17
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.8%
Fair Value
$2372.23
Current Price
$962.22
$1410.01 discount
Margin of Safety
-51.7%
Fair Value
$1.20
Current Price
$0.79
$0.41 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 178.9x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : MIST
MIST has a balanced fundamental profile.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : MIST
The primary concerns for MIST are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 7.79 is elevated, increasing financial risk.
Key Dynamics to Monitor
ARGX profiles as a growth stock while MIST is a value play — different risk/reward profiles.
MIST carries more volatility with a beta of 0.98 — expect wider price swings.
ARGX is growing revenue faster at 59.3% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 17/100), backed by strong 32.3% margins and 59.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Milestone Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular drugs. The company is headquartered in Montral, Canada.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?